Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

In the Phase III VAYHIT2 trial, ianalumab combined with eltrombopag significantly prolonged time to treatment failure and ...

Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in adults with primary immune thrombocytopenia (ITP), a B cell-driven autoimmune disease, according to phase ...

However, eltrombopag and romiplostim should never be considered as front-line treatment of the disease, George said. “These drugs are very expensive and they are maintenance therapies,” he said.

Novartis (NYSE:NVS) announced that its investigational antibody, ianalumab, combined with eltrombopag, successfully met the ...

Adults with chronic or persistent immune thrombocytopenia maintained ideal platelet counts and decreased bleeding rate after treatment with eltrombopag, according to long-term efficacy data from ...

While eltrombopag, a small-molecule non-peptide thrombopoietin receptor agonist, has been approved for children with chronic ITP, its efficacy in newly diagnosed pediatric ITP is unknown.

Eltrombopag (Promacta) generic is a thrombopoietin (TPO) receptor agonist, prescribed for immune (idiopathic) thrombocytopenic purpura (ITP). It helps the bone marrow to produce more platelets.

4.1 The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of eltrombopag, having considered evidence on the nature of chronic immune thrombocytopenia (ITP) and the ...

Eltrombopag is an oral thrombopoietin-receptor agonist approved for use in patients with chronic immune thrombocytopenia. A phase 2 study showed that eltrombopag could increase platelet counts in ...

Eltrombopag (SB-497115, GlaxoSmithKline) is a new, small-molecule, nonpeptide, oral platelet growth factor that acts as a thrombopoietin-receptor agonist.